# Maverix Biomics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/maverix-biomics

- Industry: Biotechnology
- Headquarters: San Mateo, US
- Website: www.maverixbio.com
- Total disclosed funding: $6M
- Latest round: Series A (Jan 7, 2014)
- Investors on record: 1

## About

Maverix Biomics specializes in next-generation sequencing data analysis, offering solutions that empower researchers and healthcare providers to advance scientific inquiry and clinical diagnostics.Founded in 2010 in San Mateo, US, Maverix Biomics focuses on providing advanced genomic analysis tools. The company has not undergone any major pivots but has successfully raised USD 6.00 mn in a Series A funding round on January 7, 2014, led by Asset Management Ventures, making it the sole investment target in this financing effort. Fady Magdy, the founder, has been integral to establishing the company’s direction since its inception.Maverix Biomics offers a comprehensive suite of next-generation sequencing (NGS) data analysis solutions designed to enable researchers and healthcare providers to enhance scientific discovery and clinical diagnostics. The company's core products include the Maverix Dx Platform, which simplifies the delivery of test results to clinicians through user-friendly reports, and the Maverix Complete solution, which provides researchers with a streamlined bioinformatics pipeline. Additionally, products like the RNA-Seq and DNA Variant Analysis Kits cater to a wide range of analyses across various organisms, contributing to an expanding clientele that includes academic institutions, clinical labs, and healthcare providers. The company targets markets across North America, Europe, and Asia, providing essential tools for basic research, translational medicine, and clinical diagnostics.Maverix Biomics generates revenue through the sale of its NGS analysis solutions, operating primarily on a subscription-based model alongside partnership agreements with research institutions and clinical settings. Transactions typically involve direct sales to healthcare professionals and researchers who utilize the Maverix Dx Platform and other offerings for genomic analysis. The firm’s pricing structure includes tiered plans for different levels of access to their services, encompassing both individual products and comprehensive packages like Maverix Complete and Maverix WAVES™. This transactional framework facilitates efficient access to advanced bioinformatics tools and promotes ongoing collaborations with clients, enhancing customer retention and satisfaction.Maverix Biomics plans to leverage the recent USD 6.00 mn Series A funding to enhance its product offerings and expand into new markets. The funding will be directed towards the development of upcoming products that aim to improve operational efficiency within their existing platforms. The company is targeting expansion into regions across Europe and Asia by the end of 2025, focusing on forging new partnerships and enhancing its presence in these growing markets.

## Funding rounds

- Series A, Jan 7, 2014, $6M — Asset Management Ventures

## Investors

- Asset Management Ventures (https://capitalatlas.ai/funds/asset-management-ventures) — Series A